Skip to main content
. 2020 May 11;11(5):353. doi: 10.1038/s41419-020-2566-1

Fig. 2. SC66 provokes significant apoptosis activation in RCC cells.

Fig. 2

786-O RCC cells (a–e), primary human RCC cells (“RCC1/RCC2/RCC3”, f), HK-2 tubular epithelial cells (g), or the primary human renal epithelial cells (“Ren_Epi”) (g) were treated with indicated concentration of SC66, cells were further cultured for applied time periods, caspase-3/-9 activities (a), expression of apoptosis-associated proteins (b) and cell apoptosis (c–d, f, g) were tested by the mentioned assays. For e, 786-O cells were co-treated with 50 μM of the caspase-3 inhibitor z-DEVD-cho or the pan caspase inhibitor z-VAD-cho, and cell viability was tested by MTT assay. Expression of listed proteins were quantified, normalize to Tubulin (b). For each assay, n = 5. Data were expressed as the mean ± standard deviation (S.D.). *P < 0.05 vs. “Veh” group. #P < 0.05 vs. SC66 treatment only (e). In this figure, experiments were repeated three times, and similar results were obtained each time. Bar = 100 μm (d and f).